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Identification of the fusion transcripts 




Li et al, 2011 
 RNA-Seq was performed using polyA selection. The run was analysed using a cloud version of TopHat aligment in BaseSpace.  
 TPM3 was found to be the fusion partner.  
 The two fusion transcripts identified have already been described in two cases of childhood CEL (Li et al. 2011, Rosati et al. 2006) 
 By looking at the reads in IGV viewer, we could identify « mate-pair » reads aligning to intronic regions of TPM3 and PDGFRB. 
 We then performed a PCR with primers annealing upstream of the intronic reads, and were able to localize the genomic breakpoints more precisely 
PDGFRβ exon 10 
TPM3 exon 8 
PDGFRβ intron 10.11 -  CATATACTATATGTATGTCGTAAGCCATGTACATGAGCATGCCTGTTCCTTGAACATAGGTGCAAATCCTCTGTGTGTAGATATGTAAATCGTCTA 
 
 
TPM3 intron 7.8 - CTTGTATCAGGAATGCTTGCTAAATTGTCCTT - - (90bp) - - CATCTAGCCATGAGCAACTGTGGCCTGTTGTAGCTGGGCTT 
Intronic reads identified by RNA-Seq 
The chromosomal breakpoints are located ~6kb (TPM3) and ~1,5kb (PDGFRB) further than those previously published. 
 
Conclusion 
We describe here a third  case of TPM3-PDGFRB fusion 
 
The patient was treated with imatinib therapy, responded well, and was in hematological remission at his last follow-up. 
 
RNA-Seq allows for a rapid screening of fusion transcripts and can identifiy the rare ones, for which no diagnostic test is developed for routine work. 
In addition to the « transcriptome » information, we used the « genome » information present in the data to identify the chromosomal breakpoints.  
This methodology was more time-efficient than performing a screening by PCR, and more cost-efficient than performing a whole genome sequencing. 
We received a bone marrow from a 77-year old patient presenting with hypereosinophilia. FIP1L1-PDGFRA fusion was not detected, but cytogenetic 
analysis revealed a t(1;5)(q21;q33), with locus 5q33 corresponding to PDGFRB. This was in accordance with a  diagnosis of Chronic Eosinophilic Leukemia 
(CEL), a rare subtype of myeloproliferative neoplasm, frequently characterized by rearrangements involving PDGFRA/B or FGFR1 genes. 
As FISH couldn’t identify the fusion partner of PDGFRB, we performed a whole transcriptome sequencing (or RNA-Seq). 
Introduction 
 With the same fusion transcripts previously described but  not concerning a childhood CEL 
 With chromosomal breakpoints differing from those previously described 
 
